Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Difluanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 9/20 | 0.54 |
| ▸ | OPRK1 known ✓ | P41145 | 7/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.54 |
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.54 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.54 |
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.54 |
| ▸ | OPRD1 known ✓ | P41143 | 5/20 | 0.54 |
| ▸ | HTR6 known ✓ | P50406 | 5/20 | 0.54 |
| ▸ | CACNA1C known ✓ | Q13936 | 5/20 | 0.54 |
| ▸ | CACNA1F known ✓ | O60840 | 4/20 | 0.54 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.54 |
| ▸ | HRH2 known ✓ | P25021 | 4/20 | 0.54 |
| ▸ | CACNA1D known ✓ | Q01668 | 4/20 | 0.54 |
| ▸ | CACNA1S known ✓ | Q13698 | 4/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.54 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.54 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difluanine SCHEMBL28172554 | 1.00 | SCN5A (0.57) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| Difluanine SCHEMBL1813120 | 0.99 | SCN5A (0.59) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| SCHEMBL5023656 | 0.94 | SCN5A (0.56) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| Hydrochloric Acid SCHEMBL7543578 | 0.85 | MEN1 (0.52) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| Hydrochloric Acid SCHEMBL8867248 | 0.85 | MEN1 (0.52) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| SCHEMBL8616378 | 0.83 | CYP3A4 (0.51) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| SCHEMBL4760958 | 0.83 | CYP3A4 (0.51) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| SCHEMBL8615736 | 0.83 | CYP3A4 (0.51) | SCN5AMEN1KMT2ASMN1; SMN2BLM | |
| SCHEMBL5077519 | 0.83 | HTR7 (0.67) | MEN1KMT2ASMN1; SMN2BLMPMP22 | |
| Hydrochloric Acid SCHEMBL7545277 | 0.82 | SLC6A3 (0.51) | SCN5AMEN1KMT2ASMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0946151-A1 | ASCENDING-DOSE DOSAGE FORM | ALZA CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1998023263-A1 | ASCENDING-DOSE DOSAGE FORM | ALZA CORPORATION (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | SCN5A 3628/4885SLC6A3 784/4885OPRK1 377/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | SCN5A 1958/4885SLC6A3 1243/4885OPRK1 431/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | SCN5A 2149/4885SLC6A3 916/4885OPRK1 1439/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SCN5A 28/4885SLC6A3 291/4885OPRK1 2725/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | SCN5A 364/4885SLC6A3 9/4885OPRK1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.